Anelixis Therapeutics $8.00 million Financing. Steven Perrin Filed Jun 20 D Filing

June 20, 2017 - By Vivian Currie

Anelixis Therapeutics Financing

Anelixis Therapeutics, Inc., Corporation just submitted form D because of $8.00 million equity financing. This is a new filing. Anelixis Therapeutics was able to finance itself with $4.29 million so far. That is 53.62 % of the financing offer. The total fundraising amount was $8.00 million. The form was filed on 2017-06-20. The reason for the financing was: unspecified. The fundraising still has about $3.71 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.

Anelixis Therapeutics is based in Massachusetts. The company’s business is Biotechnology. The SEC form was submitted by Steven Perrin President. The company was incorporated in 2015. The filler’s address is: 300 Technology Square, Suite 400, Cambridge, Ma, Massachusetts, 02130. Augie Nieto is the related person in the form and it has address: C/O Anelixis Therapeutics, Inc., 300 Technology Square, Suite 400, Cambridge, Ma, Massachusetts, 02130. Link to Anelixis Therapeutics Filing: 000170440017000001.

Analysis of Anelixis Therapeutics Offering

On average, firms in the Biotechnology sector, sell 73.77 % of the total offering size. Anelixis Therapeutics sold 53.62 % of the offering. The financing is still open. The average financing size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 39.27 % bigger than the average for companies in the Biotechnology sector. The minimum investment for this fundraising is set at $0. If you know more about the reasons for the fundraising, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Anelixis Therapeutics Also

The Form D signed by Steven Perrin might help Anelixis Therapeutics, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.